Orion's Darolutamide Achieves 1EP in P-III ARAMIS study in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Shots:
- The P-III ARAMIS study involves assessing of Darolutamide (600mg bid) PO vs PBO in 1500 patients in ratio (2:1) with nmCRPC who are currently being treated with ADT
- The (Androgen Receptor inhibiting Agent for MetastatIc-free Survival) study demonstrated MFS as 1EP & OS as 2EP and showed consistency with previous results in safety- efficacy and tolerability
- Darolutamide PO is an androgen receptor (AR) antagonist- jointly developed by Bayer & Orion and also received FTD from the US. Bayer plans to file its MAA on the basis of above results
/ article | Ref: Bayer | Image: 20minutos
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com